A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
AI meets AR: How Rokid Glasses bring multilingual, real-time intelligence to smart eyewear globally
Updated
March 17, 2026 1:01 AM
Rokid's smart glasses. PHOTO: ROKID
Rokid, a Chinese company specializing in AI-powered smart eyewear and human–computer interaction, has rolled out a major software update for the international version of its Rokid Glasses. This update makes it the first smart glasses manufacturer to natively support Google’s Gemini, alongside three other leading large language models: OpenAI’s ChatGPT, Alibaba’s Qwen and DeepSeek.
The integration is powered by Rokid’s device-to-cloud architecture, which enables users to switch between AI models on the fly. In practice, this means a traveler can receive a real-time translation in Japanese using one AI model, then quickly switch to ChatGPT to answer a technical query—without noticeable delay. The system also supports multi-modal inputs like voice and gestures, making interactions more intuitive for everyday use.
This is more than a routine software update. By combining AI models from both U.S. and Chinese developers, Rokid is making its smart glasses relevant to global users, with features that adapt to local languages and preferences while maintaining high performance.
These technological advancements have directly fueled Rokid’s international growth. Between November 2024 and October 2025, Shangpu Group data shows Rokid Glasses ranked No.1 in global sales for AI glasses with display functionality. Crowdfunding milestones further reflect this momentum: the product became the fastest smart glasses to raise over 100 million Japanese Yen on Japan’s MAKUAKE platform and broke Kickstarter records for smart eyewear.
Taken together, Rokid’s update highlights a shift in the smart glasses space: success increasingly comes from openness, flexibility and localized AI experiences rather than closed, single-platform ecosystems. By giving users choice, integrating global AI capabilities and bridging cultural and linguistic gaps, Rokid is positioning itself as a serious contender in the international AR and AI wearable market.